Zafgen to Present at Canaccord Genuity’s 36th Annual Growth Conference
03 août 2016 17h00 HE
|
Zafgen, Inc.
BOSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
19 juil. 2016 16h05 HE
|
Zafgen, Inc.
-ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical...
Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions
11 juin 2016 11h00 HE
|
Zafgen, Inc.
NEW ORLEANS, June 11, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity...
Zafgen Reports First Quarter 2016 Financial Results
10 mai 2016 16h05 HE
|
Larimar Therapeutics, Inc.
BOSTON, May 10, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results
03 mai 2016 16h05 HE
|
Larimar Therapeutics, Inc.
BOSTON, May 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016
03 avr. 2016 13h15 HE
|
Larimar Therapeutics, Inc.
--bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improvement in hyperphagia-related behaviors in PWS patients-- --Beloranib was associated with improvement in...
Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016
28 mars 2016 16h05 HE
|
Larimar Therapeutics, Inc.
BOSTON, March 28, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results
09 mars 2016 16h05 HE
|
Larimar Therapeutics, Inc.
BOSTON, March 09, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
Zafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors
08 mars 2016 07h00 HE
|
Larimar Therapeutics, Inc.
BOSTON, March 08, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results
02 mars 2016 16h00 HE
|
Larimar Therapeutics, Inc.
BOSTON, March 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity...